Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent

Objective: Unusual clinical course Background: Lupus anticoagulants (LA) can interfere with routine coagulation tests such as the activated partial thromboplastin time (aPTT) and prothrombin time (PT). The international normalized ratio (INR) is derived from PT and is used to monitor warfarin therap...

Full description

Bibliographic Details
Published in:AMERICAN JOURNAL OF CASE REPORTS
Main Authors: Kamal, Fatmawati; Othman, Halimatun Radziah
Format: Article
Language:English
Published: INT SCIENTIFIC INFORMATION, INC 2025
Subjects:
Online Access:https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001412816600001
author Kamal
Fatmawati; Othman
Halimatun Radziah
spellingShingle Kamal
Fatmawati; Othman
Halimatun Radziah
Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent
General & Internal Medicine
author_facet Kamal
Fatmawati; Othman
Halimatun Radziah
author_sort Kamal
spelling Kamal, Fatmawati; Othman, Halimatun Radziah
Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent
AMERICAN JOURNAL OF CASE REPORTS
English
Article
Objective: Unusual clinical course Background: Lupus anticoagulants (LA) can interfere with routine coagulation tests such as the activated partial thromboplastin time (aPTT) and prothrombin time (PT). The international normalized ratio (INR) is derived from PT and is used to monitor warfarin therapy. A positive LA result is one of the laboratory criteria of the 2023 ACR/EULAR antiphospholipid syndrome (APS) classification criteria. We report a case in which LA interfered with INR measurement in an APS patient. Case Report: Our patient was a 45-year-old man who had experienced multiple episodes of thromboembolism. His INR was consistently high, despite not being on any anticoagulant. Our laboratory used a recombinant PT reagent, Siemens Healthineers Dade (R) Innovin (R) on a fully automated coagulometer, the Sysmex CS-2500. PT measurements were repeated using 2 different analyzers, the Sysmex CA-104 and Werfen ACL Top 550 CTS. The PT results were 40.5 s (reference range (RR): 9.3-10.8 s) and 56 s, using Sysmex CS2500 and CS104, respectively. However, the PT was 13.4 s (RI: 10.3-12.7 s) using Werfen ACL Top 550 CTS. We retested the sample using Thromborel (R) S, a tissue-derived PT reagent, and PT was found to be within the reference range. The patient tested positive for LA, anti-cardiolipin, and anti-beta2 glycoprotein I antibodies. Conclusions: LA can falsely prolong the PT when a recombinant PT reagent is used. When we retested the plasma using a tissue-derived PT reagent - Thromborel (R) S - PT was within normal limits. Thus, it is important to acknowledge that LA can react differently with different PT reagents.
INT SCIENTIFIC INFORMATION, INC

1941-5923
2025
26

10.12659/AJCR.945579
General & Internal Medicine

WOS:001412816600001
https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001412816600001
title Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent
title_short Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent
title_full Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent
title_fullStr Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent
title_full_unstemmed Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent
title_sort Impact of Lupus Anticoagulant on INR Using Recombinant Prothrombin Time Reagent
container_title AMERICAN JOURNAL OF CASE REPORTS
language English
format Article
description Objective: Unusual clinical course Background: Lupus anticoagulants (LA) can interfere with routine coagulation tests such as the activated partial thromboplastin time (aPTT) and prothrombin time (PT). The international normalized ratio (INR) is derived from PT and is used to monitor warfarin therapy. A positive LA result is one of the laboratory criteria of the 2023 ACR/EULAR antiphospholipid syndrome (APS) classification criteria. We report a case in which LA interfered with INR measurement in an APS patient. Case Report: Our patient was a 45-year-old man who had experienced multiple episodes of thromboembolism. His INR was consistently high, despite not being on any anticoagulant. Our laboratory used a recombinant PT reagent, Siemens Healthineers Dade (R) Innovin (R) on a fully automated coagulometer, the Sysmex CS-2500. PT measurements were repeated using 2 different analyzers, the Sysmex CA-104 and Werfen ACL Top 550 CTS. The PT results were 40.5 s (reference range (RR): 9.3-10.8 s) and 56 s, using Sysmex CS2500 and CS104, respectively. However, the PT was 13.4 s (RI: 10.3-12.7 s) using Werfen ACL Top 550 CTS. We retested the sample using Thromborel (R) S, a tissue-derived PT reagent, and PT was found to be within the reference range. The patient tested positive for LA, anti-cardiolipin, and anti-beta2 glycoprotein I antibodies. Conclusions: LA can falsely prolong the PT when a recombinant PT reagent is used. When we retested the plasma using a tissue-derived PT reagent - Thromborel (R) S - PT was within normal limits. Thus, it is important to acknowledge that LA can react differently with different PT reagents.
publisher INT SCIENTIFIC INFORMATION, INC
issn
1941-5923
publishDate 2025
container_volume 26
container_issue
doi_str_mv 10.12659/AJCR.945579
topic General & Internal Medicine
topic_facet General & Internal Medicine
accesstype
id WOS:001412816600001
url https://www-webofscience-com.uitm.idm.oclc.org/wos/woscc/full-record/WOS:001412816600001
record_format wos
collection Web of Science (WoS)
_version_ 1825722598944669696